{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T09:09:43Z","timestamp":1789722583511,"version":"4.0.1"},"reference-count":16,"publisher":"American Society for Microbiology","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin. Vaccine Immunol."],"published-print":{"date-parts":[[2011,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>This study was done to investigate the antibody response to a Vero cell antirabies vaccine, the persistence of antibody for 5 years, and the effect of a booster dose after this interval. From August 2005 to February 2011, a total of 195 patients were enrolled into our study due to an animal bite. The Essen intramuscular (i.m.) regimen, which is recommended by the WHO for modern vaccines used in postexposure treatment, was adopted in this study. Blood samples were obtained on day 0, day 7, day 14, day 45, year 1, year 2, year 3, year 4, year 5, and year 5 plus 14 days. Immunogenicity was evaluated by the titration of neutralizing antibodies with a rapid fluorescent focus inhibition test (RFFIT). Seroconversion was expressed as the seroconversion rate (SCR). A secondary quantitative evaluation criterion, other than the seroconversion level, was the geometric mean titer (GMT). Of the 195 enrolled patients, 168 (86.4%) of them completed the whole study. No serious adverse reactions to the vaccine were reported during vaccination, the 5-year follow-up period, or revaccination. On day 14, the rabies antibody GMT value was 8.87 IU\/ml in the vaccinees. During the next 5 years, the SCR in the ChengDa vaccine group gradually decreased to 34.0% at year 5, down from 90.5% at year 1. There was a significant booster effect: the GMT was 15.22 IU\/ml on year 5 plus 14 days. Our findings demonstrate that the ChengDa rabies vaccine offers an alternative with a high degree of efficacy and yet limited side effects and ensures that the exposed patient will be on the safe side of the risk of rabies by the 14th day. Moreover, when followed by a booster dose 5 years later, it could boost the immunity. A further booster is effective in inducing a good neutralizing antibody response even after an interval of 5 years.<\/jats:p>","DOI":"10.1128\/cvi.05090-11","type":"journal-article","created":{"date-parts":[[2011,7,14]],"date-time":"2011-07-14T02:46:20Z","timestamp":1310611580000},"page":"1477-1479","source":"Crossref","is-referenced-by-count":24,"title":["Persistence of Rabies Antibody 5 Years after Postexposure Prophylaxis with Vero Cell Antirabies Vaccine and Antibody Response to a Single Booster Dose"],"prefix":"10.1128","volume":"18","author":[{"given":"Xiaowei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenggang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanlin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","published-online":{"date-parts":[[2011,7,13]]},"reference":[{"key":"key20180919073530_B1","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1001\/jama.1976.03270250019017","article-title":"Successful protection of humans exposed to rabies infection. Postexposure treatment with the new human diploid cell rabies vaccine and antirabies serum","volume":"236","author":"Bahmanyar","year":"1976","journal-title":"JAMA"},{"key":"key20180919073530_B2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0264-410X(92)90029-J","article-title":"Longevity of rabies antibody titre in recipients of human diploid cell rabies vaccine","volume":"10","author":"Briggs","year":"1992","journal-title":"Vaccine"},{"key":"key20180919073530_B3","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0167-5877(96)01113-0","article-title":"Immune response following a vaccination campaign against rabies in dogs from northwestern Spain","volume":"31","author":"Delgado","year":"1997","journal-title":"Prev Vet. Med."},{"key":"key20180919073530_B4","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1016\/j.vaccine.2005.10.015","article-title":"Preventing the incurable: Asian rabies experts advocate rabies control","volume":"24","author":"Dodet","year":"2006","journal-title":"Vaccine"},{"key":"key20180919073530_B5","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1001\/jama.1981.03320200020017","article-title":"Booster effect of human diploid cell antirabies vaccine in previously treated persons","volume":"246","author":"Fayaz","year":"1981","journal-title":"JAMA"},{"key":"key20180919073530_B6","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0188-4409(02)00381-8","article-title":"Infectious diseases in Mexico. A survey from 1995\u20132000","volume":"33","author":"Flisser","year":"2002","journal-title":"Arch. Med. Res."},{"key":"key20180919073530_B7","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/004947550003000108","article-title":"Developments in the production and application of rabies vaccine for human use in China","volume":"30","author":"Lin","year":"2000","journal-title":"Trop. Doct."},{"key":"key20180919073530_B8","first-page":"27","article-title":"Polio and rabies vaccines produced in continuous cell lines: a reality for Vero cell line","volume":"70","author":"Montagnon","year":"1989","journal-title":"Dev. Biol. Stand."},{"key":"key20180919073530_B9","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1093\/infdis\/137.6.783","article-title":"Immunization with a human diploid cell strain of rabies virus vaccine: two-year results","volume":"137","author":"Nicholson","year":"1978","journal-title":"J. Infect. Dis."},{"key":"key20180919073530_B10","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/clinids\/2.3.433","article-title":"Rabies vaccine prepared in human cell cultures: progress and perspectives","volume":"2","author":"Plotkin","year":"1980","journal-title":"Rev. Infect. Dis."},{"key":"key20180919073530_B11","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/1471-2334-8-113","article-title":"Rabies trend in China (1990-2007) and post-exposure prophylaxis in the Guangdong province","volume":"8","author":"Si","year":"2008","journal-title":"BMC Infect. Dis."},{"key":"key20180919073530_B12","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1086\/515267","article-title":"Antibody persistence following preexposure regimens of cell-culture rabies vaccines: 10-year follow-up and proposal for a new booster policy","volume":"177","author":"Strady","year":"1998","journal-title":"J. Infect. Dis."},{"key":"key20180919073530_B13","first-page":"41","article-title":"Rabies and post-exposure prophylaxis in Thai children","volume":"7","author":"Thongcharoen","year":"1989","journal-title":"Asian Pac. J. Allergy Immunol."},{"key":"key20180919073530_B14","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1128\/CVI.00433-09","article-title":"Promising rabies vaccine for postexposure prophylaxis in developing countries, a purified Vero cell vaccine produced in China","volume":"17","author":"Wang","year":"2010","journal-title":"Clin. Vaccine Immunol."},{"key":"key20180919073530_B15","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/S0264-410X(02)00585-6","article-title":"The challenge to provide affordable rabies post-exposure treatment","volume":"21","author":"Warrell","year":"2003","journal-title":"Vaccine"},{"key":"key20180919073530_B16","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0092-1157(79)80024-4","article-title":"A microtest for the quantitation of rabies virus neutralizing antibodies","volume":"7","author":"Zalan","year":"1979","journal-title":"J. Biol. Stand."}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1128\/CVI.05090-11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:45:46Z","timestamp":1627591546000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.05090-11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,13]]},"references-count":16,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2011,8,31]]},"published-print":{"date-parts":[[2011,9]]}},"alternative-id":["10.1128\/CVI.05090-11"],"URL":"https:\/\/doi.org\/10.1128\/cvi.05090-11","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,13]]}}}